Table 2. Patient and treatment features according to different tumor locations (n=285).
| Variables | Outer quadrant, n (%) | Upper-inner quadrant, n (%) | Lower-inner/central, n (%) | P value |
|---|---|---|---|---|
| Age (years) | 0.841 | |||
| >50 | 54 (33.8) | 22 (37.9) | 24 (35.8) | |
| ≤50 | 106 (66.2) | 36 (62.1) | 43 (64.2) | |
| Clinical stage | 0.181 | |||
| II | 61 (38.1) | 29 (50.0) | 28 (41.8) | |
| III | 99 (61.9) | 29 (50.0) | 39 (58.2) | |
| Histological grade | 0.15 | |||
| I | 15 (9.4) | 10 (17.2) | 5 (7.5) | |
| II | 130 (81.3) | 46 (79.3) | 53 (79.1) | |
| III | 15 (9.3) | 2 (3.5) | 9 (13.4) | |
| PR status | 0.251 | |||
| Positive | 84 (52.5) | 36 (62.1) | 34 (50.7) | |
| Negative | 76 (47.5) | 22 (37.9) | 33 (49.3) | |
| ypN0 | 0.925 | |||
| Yes | 44 (27.5) | 17 (29.3) | 20 (29.9) | |
| No | 116 (72.5) | 41 (70.7) | 47 (70.1) | |
| Luminal subtype | 0.953 | |||
| Luminal A | 60 (37.5) | 23 (39.7) | 26 (38.8) | |
| Luminal B | 100 (62.5) | 35 (60.3) | 41 (61.2) | |
| Margin | 0.604 | |||
| Negative | 145 (90.6) | 55 (94.8) | 61(91.0) | |
| Positive | 15 (9.3) | 3 (5.2) | 6 (9.0) | |
| NAC regimen | 0.974 | |||
| TC | 24 (15.0) | 8 (13.8) | 10 (14.9) | |
| AT | 136 (85.0) | 50 (86.2) | 57 (85.1) | |
| IMN-RT | <0.001 | |||
| Yes | 27 (16.9) | 19 (32.8) | 12 (17.9) | |
| No | 133 (83.1) | 39 (67.2) | 55 (82.1) | |
| Type of surgery | 0.222 | |||
| BCS | 39 (24.4) | 21 (36.2) | 18 (26.9) | |
| MRM | 121 (75.6) | 37 (63.8) | 49 (73.1) | |
| Standard endocrine therapy | 0.255 | |||
| Yes | 112 (70.0) | 43 (74.1) | 54 (80.6) | |
| No | 48 (30.0) | 15 (25.9) | 13 (19.4) | |
| Pathological stage | 0.400 | |||
| 0–II | 127 (79.4) | 41 (70.7) | 52 (77.6) | |
| III | 33 (20.6) | 17 (29.3) | 15 (22.4) | |
| RT | 0.867 | |||
| Yes | 75 (46.9) | 32 (55.2) | 42 (62.7) | |
| No | 85 (53.1) | 26 (44.8) | 25 (37.3) | |
| Pathological stage | 0.080 | |||
| II | 118 (73.8) | 48 (82.8) | 58 (86.6) | |
| III | 42 (26.2) | 10 (17.2) | 9 (13.4) | |
| LMR | 0.686 | |||
| >5.2 | 99 (61.9) | 35 (60.3) | 42 (62.7) | |
| ≤5.2 | 61 (38.1) | 23 (39.7) | 25 (37.3) | |
| pCR | 0.236 | |||
| Yes | 13 (8.1) | 8 (13.8) | 10 (14.9) | |
| No | 147 (91.9) | 50 (86.2) | 57 (85.1) | |
AT, doxorubicin docetaxel; BCS, breast-conserving surgery; IMN-RT, internal mammary node radiotherapy; LMR, lymphocyte-to-monocyte ratio; MRM, modified radical mastectomy, NAC, neoadjuvant chemotherapy; pCR, pathological complete response; PR, progesterone receptor; RT, radiation therapy; TC, docetaxel cyclophosphamide; ypN0, N0 after neoadjuvant chemotherapy.